Proposal:Breast Cancer in Hispanic Populations
Patients’ preferences for post-treatment breast cancer follow-up in primary care vs. secondary care: a qualitative study
Carriene Roorda MSc,* Geertruida H. de Bock PhD,† Christian Scholing MD MSc,‡ Klaas van der Meer MD PhD,§ Marjolein Y. Berger MD PhD,¶ Marlieke de Fouw MD MSc** and Annette J. Berendsen MD PhD†† *Epidemiologist, PhD candidate, Department of General Practice, Department of Epidemiology, University of Groningen,
University Medical Center Groningen,†Epidemiologist, Professor in Oncological Epidemiology, Department of Epidemiology,
University of Groningen, University Medical Center Groningen, ‡Emergency Medicine Registrar, §Professor in General Practice
Medicine, Former Head of the Department of General Practice, ¶Professor in General Practice Medicine, Head of the Depart-
ment of General Practice, **Physician in Tropical Medicine and International Health and ††Assistant Professor, Department of
General Practice, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
Correspondence Carriene Roorda MSc
Department of General Practice
University of Groningen
University Medical Center Groningen
P.O. Box 196
9700 AD Groningen
The Netherlands
E-mail: [email protected]
Accepted for publication
22 February 2014
Keywords: breast cancer, follow-up,
interviews, patients’ preferences,
primary care, qualitative study
Abstract
Objective To explore patients’ preferences for follow-up in primary
care vs. secondary care.
Methods A cross-sectional design was employed, involving semi-
structured interviews with 70 female patients with a history of
early-stage breast cancer. Using descriptive content analysis, inter-
view transcripts were analysed independently and thematically by
two researchers.
Findings Patients expressed the strongest preference for annual vis-
its (31/68), a schedule with a decreasing frequency over time (27/
68), and follow-up > 10 years, including lifelong follow-up (20/64). The majority (56/61) preferred to receive follow-up care from the
same care provider over time, for reasons related to a personal
doctor–patient relationship and the physician’s knowledge of the patient’s history. About 75% (43/56) preferred specialist follow-up
to other follow-up models. However, primary care-based follow-up
would be accepted by 57% (39/68) provided that there is good
communication between GPs and specialists, and sufficient knowl-
edge among GPs about follow-up. Perceived benefits of primary
care-based follow-up referred to the personal nature of the GP– patient relationship and the easy access to primary care. Perceived
barriers included limited oncology knowledge and skills, time
available, motivation among GPs to provide follow-up care and
patients’ confidence with the present specialist follow-up.
Conclusions More than half of the patients were open to primary
care-based follow-up. Patients’ confidence with this follow-up
model may increase by using survivorship care plans to facilitate
communication across the primary/secondary interface and with
patients. Training GPs to improve their oncology knowledge and
skills might also increase patients’ confidence.
2192 ª 2014 John Wiley & Sons Ltd Health Expectations, 18, pp.2192–2201
doi: 10.1111/hex.12189
Introduction
Breast cancer is the most common malignancy
and the leading cause of cancer-related death in
women worldwide, accounting for 23% of new
cancer cases and 14% of cancer deaths in 2008. 1
Survival of breast cancer patients has increased
in many countries as a result of early detection
through mammography and improved treat-
ment. 1 This will place an increasing burden on
follow-up oncology clinics 2 and primary care,
due to the demand for cancer surveillance after
completion of primary treatment and general
medical care for co-morbid conditions. 3 This
highlights the need for an effective resource allo-
cation between primary care and hospital care
in the future, and possible transfer of follow-up
to the general practitioner (GP). 3
Transfer of breast cancer follow-up to the
primary care setting has to be accepted by all
parties involved, including the patients. In two
cross-sectional surveys, 4,5
and a discrete choice
experiment 6
most patients with a history of
breast cancer preferred specialist follow-up to
GP-led follow-up. In two surveys, primary
care-based follow-up was acceptable to 5–39% of the patients
7,8 and to 55 and 67% of
patients invited to participate in two random-
ized clinical trials comparing hospital and
primary care-based breast cancer follow-up. 9,10
However, these studies used quantitative meth-
ods and were performed in a hospital setting.
Qualitative research can provide a deeper
understanding of the (non-)acceptance of pri-
mary care-based follow-up by patients. To our
knowledge, three qualitative studies have
explored patients’ preferences concerning pri-
mary care-based follow-up. One study reported
that Australian breast cancer survivors are will-
ing to accept an increased role for their GP in
a shared care model, 11,12
while in another study
US breast cancer survivors do not think that
their primary care physician has a central role
in their survivorship care. 13
An earlier study
found that UK patients prefer access to spe-
cialist services, particularly during the early
stages of follow-up. 14
As health-care systems
may differ between countries worldwide, more
qualitative research concerning patients’ prefer-
ences in the issue of primary care-based follow-
up is needed. We conducted a qualitative study
among Dutch patients recruited in general
practice, in which the aim was to describe
patients’ preferences for follow-up in primary
care vs. secondary care.
Methods
Design and setting
A qualitative study was performed in the con-
text of the Dutch healthcare system, in which
primary care has played a central role for
many years. Almost all citizens are registered
with a GP, who deals with 95% of health
problems presented by patients. 15
At the time
this study was conducted, the Dutch breast
cancer guidelines recommended hospital fol-
low-up for 5 years, including yearly mam-
mography. Physical examination had to be
performed every 3 months in the first year,
every 6 months in the second year and annu-
ally thereafter. After 5 years, yearly follow-up
visits and mammography appointments in the
hospital were recommended for patients
aged ≤ 60 years. Patients aged > 60 years who had undergone mastectomy had to be referred
to the national screening programme for
two-yearly mammography. For patients
aged > 60 years, and treated with breast- conserving therapy, discharge to their GP for
yearly physical examination was recommended,
combined with two-yearly mammographic fol-
low-up in the hospital. 16,17
A cross-sectional design was employed,
involving semi-structured interviews with 70
female patients with a history of early-stage
breast cancer recruited from GP offices of the
Registration Network Groningen (RNG). This
general practice research network was
established in 1989 and consists of three group
practices with 17 GPs and a dynamic popula-
tion of about 30 000 patients in the city of
Groningen and the smaller towns Hoogeveen
and Sappemeer in the northern part of the
Netherlands. 18
To protect patient identity, ref-
ª 2014 John Wiley & Sons Ltd Health Expectations, 18, pp.2192–2201
Patients’ preferences for breast cancer follow-up, C Roorda et al. 2193
erence numbers were assigned, and data were
stored against these numbers. According to the
Institutional Review Board of the University
Medical Center Groningen (UMCG), no
approval was needed as this non-invasive study
was not subject to the Dutch Medical Research
Involving Human Subjects Act. The principal
aim of this Act is to provide protection for
human subjects who take part in medical
research. 19,20
Recruitment of patients
Using the RNG database, we searched for
patients who had a recorded code for female
breast malignancy in their record between 1998
and 2007 and who were also registered with a
participating GP at the start of the study (1
January 2009). We identified 167 of such
patients (Fig. 1). Confirmation of breast cancer
in history was obtained by going back to the
participating general practices; subsequently,
additional information about breast cancer
diagnosis, stages, treatments and recurrences
was collected for these women. 18
GPs from the
RNG were asked to include patients with a
history of breast cancer who were able to par-
ticipate in the study. A total of 18 patients
were excluded from the study for the reasons
shown in Fig. 1. Patients with distant metasta-
sis at diagnosis or during follow-up were
excluded because they are expected to use more
(palliative) health care in general practice than
patients treated with curative intent. Eligible
patients (n = 149) were sent a letter, an infor- mation leaflet about the study and an informed
consent form by their own GP, to ensure that
only patients who gave their written informed
consent (n = 72) were contacted and inter- viewed by the researchers. Two patients were
excluded after interviewing because of distant
metastasis during follow-up, or missing data.
Interview guide development and data
collection
Based on a literature review and interviews
with three patients not linked to the RNG, a
semi-structured interview guide was developed.
The introductory part of this guide addressed
Breast cancer in history and registered with a participating GP at the start of study (n = 167)
Not able to participate in the study according to the GP and excluded (n = 18): ♦ Not registered with the GP any longer (n = 6) ♦ Dutch not first language (n = 1) ♦ Cognitive and psychological problems (n = 7) ♦ Too old (n = 1) ♦ Treatment in another country (n =1 ) ♦ Undergoing investigations for possible distant metastasis (n = 1) ♦ Still undergoing breast cancer treatment (n = 1)
Excluded from the analysis (n = 2): ♦ Distant meta
Patients preferences for follow-up were not discussed (n = 1) stasis during follow-up (n = 1)
♦
Able to participate in the study according to the GP (n =149)
Excluded (n = 77): ♦ Did not respond (n = 75) ♦ Gave informed consent but declined to participate (n = 2)
Gave informed consent (n = 72) and were interviewed
Included in the analysis (n =70) Figure 1 Flow diagram of the
identification and inclusion of patients
with early-stage breast cancer.
ª 2014 John Wiley & Sons Ltd Health Expectations, 18, pp.2192–2201
Patients’ preferences for breast cancer follow-up, C Roorda et al.2194
patients’ experiences with diagnosis, treatment
and follow-up to let patients ‘tell their story’ of
the breast cancer experience. The first part
focused on patients’ preferences for follow-up
in primary care vs. secondary care; The second
part focused on patients’ perceptions of the
aims of follow-up (Appendix S1). In this arti-
cle, we report on patients’ preferences for fol-
low-up. To test the interview guide, pilot
interviews were conducted with 10 patients
from the RNG. Themes related to care pro-
vider continuity emerged from these interviews
and were added to the interview guide. The
final interview guide was used in the remaining
62 interviews.
Most interviews were conducted by a final
year medical student (CS, male), who had com-
pleted his clinical training and participated in
the research project to finish his Master’s
degree. He had passed the tests related to
learning communication skills and clinical
interviewing, as these are part of the medical
school curriculum. One patient requested to be
interviewed by a female researcher (CR).
Patients were interviewed individually in their
own home (n = 69), in the general practice (n = 2) or at our Department of General Prac- tice (n = 1). Each interview lasted 30–60 min, was audio-recorded and transcribed verbatim.
Confidentiality of the interview data was dis-
cussed at the beginning of the interviews.
Patients were assured that their data would be
processed and analysed anonymously.
No relationship was established between the
researchers and the patients prior to study com-
mencement. Before being contacted, the patient
did not know anything about the researchers,
except for a name, occupation and the reason
for conducting the interview. This information
was provided in the letter, the information
leaflet and the informed consent form. Further-
more, the researchers briefly introduced
themselves at the beginning of the interview.
Data analysis
Descriptive statistics were used to describe
patients’ characteristics. Interview data were
coded by two researchers using descriptive
content analysis. 21
First, one researcher (MdF,
female) organized transcribed text concerning
patients’ preferences for follow-up into display
tables, as described by Miles and Huberman. 22
Next, two researchers independently reviewed
these tables and coded patients’ responses
based upon the predetermined themes in the
interview guide (Table 1). The researchers dis-
cussed any discrepancies in the findings until
consensus was reached. Summaries were writ-
ten and illustrated with quotes of patients. For
the predetermined themes, the numbers of
responses were counted. In this way, a cross-
case approach with a variable-oriented strategy
was used in the data analysis. 22,23
Data
saturation was not determined as data analysis
took place after completion of data collection.
However, after analysing the majority of the
interviews, no new themes appeared indicating
saturation.
Results
Characteristics of the included patients are
presented in Table 2. Median age at the time
of the interview was 62.6 (range 34.5–88.4) years. Median time since breast cancer
diagnosis was 7.0 (range 1.0–23.1) years. No significant differences were found between the
characteristics of the included patients (n = 70) and the non-respondents/excluded patients
(n = 79) (data not shown).
Table 1 Patients’ preferences for follow-up: predetermined themes
Discussed,
n (%)
Follow-up frequency 68 (97.1)
Follow-up duration 64 (91.4)
Care provider continuity* 61 (87.1)
Care provider: first choice 56 (80.0)
GP-led follow-up 68 (97.1)
Care provider continuity:
GP vs. specialists*
38 (54.3)
*These themes emerged from the pilot-interviews (n = 10) and were added to the interview guide after these interviews.
ª 2014 John Wiley & Sons Ltd Health Expectations, 18, pp.2192–2201
Patients’ preferences for breast cancer follow-up, C Roorda et al. 2195
Follow-up frequency
Patients expressed the strongest preference for
annual visits (31/68) (Table 3). Other fre-
quently mentioned options included visits
twice a year (10/68) and a schedule with a
decreasing frequency over time (10/68). During
the interviews, 27 patients said they would
(also) like a schedule with a decreasing fre-
quency over time.
Annual visits
For all that fuss I think once a year is certainly
enough; I don’t need to have that mammogram
more often. (P21, age 65 years)
A schedule with a decreasing frequency over
time
Well, 3 months and then half a year, that scaling
down, I like that. And then after 2 years, once
every year. Yes, I think that’s good. (P06, age
86 years)
Follow-up duration
The most preferred duration of follow-up
was > 10 years, including lifelong follow-up (20/64) (Table 3). Other frequently mentioned
options were 10 years of follow-up (16/64) and
5 years of follow-up (8/64).
Over 10 years, including lifelong follow-up
The way I think about it now: maybe forever.
Only it was 5 years ago. . . and after 10 years I
might say, of course not. But that feeling, it does
gives you a bit of security, if you’re checked at
Table 2 Characteristics of the patients included in the analysis
n = 70
Age at diagnosis,
median (range), years
55.2 (27.4–83.9)
Breast cancer
T stage, n (%)
Tis/T1 43 (64.2)
T2/T3/T4 24 (35.8)
Unknown 3
Breast cancer
N stage, n (%)
N0 48 (68.6)
N+ 22 (31.4)
Unknown
Surgery, n (%)
Lumpectomy* 40 (57.1)
Mastectomy †
30 (42.9)
Systemic treatment, n (%)
None 12 (17.1)
Chemotherapy 35 (50.0)
Endocrine therapy 16 (22.9)
Chemotherapy +
endocrine therapy
7 (10.0)
Recurrent breast cancer
during follow-up, n (%)
Locoregional 3 (4.3)
Contralateral 2 (2.9)
Age at time of interview,
median (range), years
62.6 (34.5–88.4)
Time since diagnosis,
median (range), years
7.0 (1.0–23.1)
*Including patients treated with lumpectomy, with and without
radiation therapy. † Including patients treated with lumpectomy followed by
mastectomy, with and without radiation therapy.
Table 3 Patients’ preferences for follow-up: frequency and duration
n (%)
Frequency (n = 68)
< Every year 2 (2.9)
Every year 31 (45.6)
Twice a year 10 (14.7)
> Twice a year 6 (8.8)
Not more/less often
than at present
6 (8.8)
Decreasing frequency
over time*
10 (14.7)
Other 3 (4.4)
Duration (n = 64)
< 5 years 1 (1.6)
5 years 8 (12.5)
7 years 2 (3.1)
10 years 16 (23.5)
> 10 years 20 (31.3)
Lifelong 11 (17.2)
At least 5 years 3 (4.7)
Longer than at present 2 (3.1)
Duration recommended
by the specialist
2 (3.1)
No preference 2 (3.1)
Other 8 (12.5)
*Of all patients (n = 68), 27 would (also) like a schedule with a decreasing frequency over time.
ª 2014 John Wiley & Sons Ltd Health Expectations, 18, pp.2192–2201
Patients’ preferences for breast cancer follow-up, C Roorda et al.2196
least once a year . . . So, as far as I’m concerned
I’d go for the expensive solution - let them go on
controlling me for a long time. . . (P33, age
57 years)
Care provider continuity
The majority of patients (56/61) preferred to
receive follow-up care from the same care pro-
vider at each visit. Most explanations for this
preference are related to a personal doctor– patient relationship (of trust) and the physi-
cians’ knowledge of the patients’ history (so
that patients do not have to present their story
over and over again). Three patients considered
a lack of care continuity as an advantage in
terms of receiving different opinions. Two oth-
ers declared that they were neutral with respect
to care provider continuity.
A personal doctor–patient relationship
Great. You build up a sort of band. If it would
be someone else every time, then I’d think: what
have I got now. They do have something on
paper, but still . . .. I wouldn’t like to keep having
a different GP. (P39, age 72 years)
Knowledge of the patients’ history
Then Doctor X was sick, and then another doc-
tor came who said: 4 years tamoxifen? Not
5 years? And then I had to explain that. . .. and
then another doctor came and then something
else was unclear . . . but because it was someone
else every time, I found that very unpleasant.
(P67, age 34 years)
Follow-up care provider: first choice
During the interviews, patients were asked
which care provider should provide their fol-
low-up. About 75% (43/56) preferred specialist
follow-up to other follow-up models, including
GP-led follow-up (4/56), nurse-led follow-up
(2/56) and follow-up alternately provided by
specialist and/or GP and/or nurse (5/56). Two
patients preferred to receive follow-up care
from someone who can best provide this care.
Specialist follow-up
Well, you could say the GP because he knows
you the best. But yes, the surgeon really knows
more about it . . .. So yes, then rather the sur-
geon. (P30, age 48 years)
GP-led follow-up
Follow-up provided by the GP would be
accepted by 57% of patients (39/68) (Table 4).
One of these patients found this follow-up
Table 4 Patients’ preferences for follow-up provided by the general practitioner (GP) (n = 68)
n (%)
Acceptance
There is a GP-patient relationship
of trust
39 (57.4)
Patient receives more personal
attention in general practice than
in the hospital
General practice is nearby
General practice is easily accessible
Provided that there is good
communication between
the GP and specialists
Provided that the GP has sufficient
knowledge about follow-up
No acceptance
GP has a broad medical knowledge 28 (41.2)
GP is not specialised/educated
in follow-up
GP has insufficient experience/
knowledge regarding follow-up
GP has too little time available/
high workload for providing
follow-up
GP is not motivated to provide
follow-up
Patient has less confidence in GP/
more confidence in specialists
Patient feels confident/is satisfied
with present hospital follow-up
GP missed breast cancer diagnosis
GP has to refer patients to the hospital
GP was not involved during
the active treatment phase
Mammography has to be
performed in the hospital
There are effective links within the hospital
Neutral 1 (1.5)
ª 2014 John Wiley & Sons Ltd Health Expectations, 18, pp.2192–2201
Patients’ preferences for breast cancer follow-up, C Roorda et al. 2197
model acceptable after 5 years of hospital
follow-up. Another commented that she would
only accept follow-up provided by her own GP
(and not by other GPs). None of the characteris-
tics presented in Table 2 were significantly asso-
ciated with patients’ willingness to accept GP-
led follow-up (data not shown). Patients’
motives for accepting this follow-up model
included having a relationship of trust with the
GP, receiving more personal attention in general
practice than in the hospital, and having less
travelling/waiting time as the general practice is
nearby and easily accessible. However, good
communication between GPs and specialists and
sufficient knowledge among GPs about follow-
up, were considered essential by the patients.
Less travelling time
Well, I’d approve of that . . . As you get older,
that’s much better for us. Because it’s close by
and then you don’t have to go to the hospital
and you don’t have that dreadful waiting room.
(P58, age 70 years)
Good communication/sufficient knowledge
I find that OK, as long as he discusses everything
with the various doctors and he stays up to date.
Because in general the GP is a bit less up to date
about what’s really going on in terms of thera-
pies. (P10, age 36 years)
Follow-up provided by the GP would not be
accepted by 41% (28/68) (Table 4). One patient
felt neutral with respect to GP led follow-up.
Patients who found GP-led follow-up unaccept-
able were concerned about (limited) oncology
education, knowledge and experience among
GPs (Table 4). Furthermore, they thought that
GPs had too little time available and were not
motivated to provide follow-up care. Patients
expressed less confidence in their GP and more
confidence in specialists with respect to breast
cancer follow-up. Also, patients were satisfied
with the present hospital follow-up. Other barri-
ers to GP-led follow-up included GPs missing
breast cancer diagnosis, GPs seen as referring
agents to the hospital, no GP involvement dur-
ing the active treatment phase, mammography
appointments in the hospital and perceived
effective links within the hospital.
GPs’ limited experience
I think - the more experienced your fingers are,
the faster you can detect something . . . And a
GP has just seen someone with a runny nose,
and then I come in between with my breasts,
because there’s also a man with a sore toe wait-
ing. According to my feeling, it seems better to
have someone do this - who’s doing this every
single day. (P44, age 61 years)
Care provider continuity: GP vs. specialists
When patients could choose between follow-up
provided by their own GP vs. follow-up
provided by different specialists (lack of care
provider continuity), 55% of these patients (21/
38) would choose the first option, while 34%
(13/38) preferred the second option. In that
case, two patients would terminate follow-up.
One patient would go to another hospital for
follow-up, while another patient stated she had
no preference for either of the options.
GP-led follow-up
Yes, then rather with the GP - that’s the contact
that you still have. And also . . . the feeling that
there’s attention for you at that moment, instead
of being just a number on a letter, and someone
just gives you the message (P62, age 55 years)
Discussion
This qualitative study explored preferences for
breast cancer follow-up in primary care vs. sec-
ondary care, among female patients with a his-
tory of early-stage breast cancer recruited in
general practice. The women expressed the
strongest preference for annual visits, a schedule
with a decreasing frequency over time, and fol-
low-up > 10 years, including lifelong follow-up. The majority preferred to receive follow-up care
from the same care provider over time, for
reasons related to a personal doctor–patient relationship and the physicians’ knowledge of
ª 2014 John Wiley & Sons Ltd Health Expectations, 18, pp.2192–2201
Patients’ preferences for breast cancer follow-up, C Roorda et al.2198
the patients’ history. About 75% preferred
specialist follow-up to other follow-up models.
However, follow-up by the GP would be
accepted by 57%, provided that there is good
communication between GPs and specialists
and sufficient knowledge among GPs about
follow-up. Perceived benefits of GP-led follow-
up referred to the personal nature of the GP– patient relationship and the easy access to pri-
mary care. Perceived barriers to GP-led follow-
up included limited oncology knowledge and
skills, time available, motivation among GPs to
provide follow-up care and patients’ confidence
with the present specialist follow-up.
In line with our results, others have also
shown that patients with a history of breast
cancer and participating in a hospital follow-
up programme strongly prefer visits once or
twice a year (depending on time since treat-
ment) and lifelong follow-up. 4,8
Before entering
hospital follow-up, most patients expect to go
back to the clinic once or twice a year, but are
uncertain as to how long they would remain in
follow-up. 24
As in our study, others also
reported the importance of care provider conti-
nuity. 7,11,12,14,25,26
Among Australian breast
cancer survivors, the main reason for prefer-
ring to receive follow-up care from the
same care provider over time was the doctor-
patient relationship developed during the active
treatment phase. 12
Our study supports earlier quantitative 4–6
and qualitative 11–13
findings that patients with a
history of breast cancer prefer specialist follow-
up to primary care-based follow-up. When
interpreting these findings, it should be kept in
mind that patients tend to prefer the most
familiar situation. 4,6
In our study, all patients
were diagnosed with breast cancer before 2008;
at that time, Dutch GPs did not play a formal
role in breast cancer follow-up care. Other stud-
ies reported that patients who already received
breast cancer follow-up or survivorship care
from their primary care physician were satisfied
with it 27–29
and did not report any disadvan-
tage. 11
Furthermore, patients’ preference for
specialist follow-up seems to be related to a
strong specialist–patient relationship developed
during the active treatment phase. 11,12
If fol-
low-up is transferred to the primary care set-
ting, formal involvement of GPs during the
active treatment phase might increase
patient’s confidence with primary care-based
follow-up.
In the present study, despite patients’ prefer-
ence for specialist follow-up, primary care-
based follow-up was acceptable to 57% of
patients, compared to 5–39% of patients in two surveys
7,8 and 55 and 67% of patients par-
ticipating in two randomized clinical trials. 9,10
Patients in our study, similar to patients in an
Australian qualitative study, 11,12
considered the
GP–patient relationship and the easy access to primary care as benefits of primary care-based
follow-up. However, good communication
between GPs and specialists and sufficient
knowledge among GPs about follow-up were
regarded as prerequisites to accept this follow-
up model. Breast cancer survivors in other
countries found deficiencies in the communica-
tion between primary care and specialist
care 12,28
and felt that written documentation or
on-going communication between their
specialists and primary care physicians would
be helpful in coordinating their care. 13
Therefore, survivorship care plans may be
useful instruments to facilitate communication
among patients and health-care providers. 30–32
Limited education, knowledge, experience,
time and motivation among GPs were per-
ceived barriers for the patients both in our
study and in three previous qualitative stud-
ies 11–14
to accept primary care-based follow-up.
Furthermore, in another qualitative study, the
majority of women receiving hospital follow-up
care (n = 15) did not contact their GP because they considered them to be too busy or to be
lacking in specialist knowledge. 26
Informing
women of the educational activities of their GP
might increase their confidence with primary
care-based follow-up. 11
Major strengths of this study are the large
sample of participants (n = 70) recruited in a community setting (general practice) and that
the sample covers the preferences for follow-up
of women (aged 34–88 years) with a history of
ª 2014 John Wiley & Sons Ltd Health Expectations, 18, pp.2192–2201
Patients’ preferences for breast cancer follow-up, C Roorda et al. 2199
breast cancer and living from 1 to 23 years
after diagnosis. Trustworthiness of the findings
was enhanced by the use of verbatim
transcripts and by using two researchers to
code patients’ responses based upon the
predetermined themes in the interview guide.
Member checking (whereby participants pro-
vide feedback on the preliminary analysis) was
not performed as we considered this to be too
time-consuming for the patients. The main lim-
itation of this study concerns incomplete data
collection in the way that not all predetermined
themes in the interview guide were discussed
with all patients. As the flow of the dialogue
was mainly set by the patients, the (main)
interviewer did not strictly follow the interview
guide over time, probably due to limited
interviewing experience. The fact that predeter-
mined themes in the interview guide were not
discussed with all patients was discovered
during data analysis as the interviews were
analysed at the end, rather than in an iterative
process. As gender mediates the production
and analysis of qualitative data, 33
another limi-
tation might be that female breast cancer
patients in the present study were interviewed
by a male interviewer. However, only one
patient specifically requested to be interviewed
by a female researcher. Furthermore, tran-
scribed text showed that patients spoke freely
about their preferences for follow-up. There-
fore, we do not believe that using a male inter-
viewer seriously affected patients’ responses
concerning their preferences for follow-up.
In summary, over 50% of patients were open
to the possibility of primary care-based follow-
up. Patients’ confidence with this follow-up
model may increase by using survivorship care
plans to facilitate communication across the
primary/secondary interface and with patients.
Training GPs to improve their oncology
knowledge/skills might also serve to improve
patients’ confidence.
Acknowledgements
The authors are grateful to the women who
gave their time to be interviewed. We thank
the general practitioners from the Registration
Network Groningen for their help during data
collection in the general practices and for the
inclusion of patients with a history of breast
cancer in this study.
Sources of Funding
This study was supported by a grant from the
Stoffels-Hornstra Foundation, Coevorden, The
Netherlands.
Conflict of Interest
No conflict of interests have been declared.
Supporting Information
Additional Supporting Information may be
found in the online version of this article: Appendix S1. Main part of the semi-
structured interview guide.
References
1 Jemal A, Bray F, Center MM, Ferlay J, Ward E,
Forman D. Global cancer statistics. CA: A Cancer
Journal for Clinicians, 2011; 61: 69–90. 2 Rutgers EJ. Follow-up care in breast cancer. Expert
Review of Anticancer Therapy, 2004; 4: 212–218. 3 Knottnerus JA, Wijffels JFAM, eds. Nazorg bij
kanker: de rol van de eerstelijn. Amsterdam: KWF
Kankerbestrijding, 2011.
4 de Bock GH, Bonnema J, Zwaan RE, van de Velde
CJ, Kievit J, Stiggelbout AM. Patient’s needs and
preferences in routine follow-up after treatment for
breast cancer. British Journal of Cancer, 2004; 90:
1144–1150. 5 Mayer EL, Gropper AB, Neville BA et al. Breast
cancer survivors’ perceptions of survivorship care
options. Journal of Clinical Oncology, 2012; 30:
158–163. 6 Kimman ML, Dellaert BG, Boersma LJ, Lambin P,
Dirksen CD. Follow-up after treatment for breast
cancer: one strategy fits all? An investigation of
patient preferences using a discrete choice
experiment. Acta Oncologica, 2010; 49: 328–337. 7 Renton JP, Twelves CJ, Yuille FA. Follow-up in
women with breast cancer: the patients’ perspective.
Breast, 2002; 11: 257–261. 8 van Hezewijk M, Ranke GM, van Nes JG,
Stiggelbout AM, de Bock GH, van de Velde CJ.
ª 2014 John Wiley & Sons Ltd Health Expectations, 18, pp.2192–2201
Patients’ preferences for breast cancer follow-up, C Roorda et al.2200
Patients’ needs and preferences in routine follow-up
for early breast cancer; an evaluation of the
changing role of the nurse practitioner. European
Journal of Surgical Oncology, 2011; 37: 765–773. 9 Grunfeld E, Mant D, Yudkin P et al. Routine
follow up of breast cancer in primary care:
randomised trial. British Medical Journal, 1996; 313:
665–669. 10 Grunfeld E, Levine MN, Julian JA et al.
Randomized trial of long-term follow-up for early-
stage breast cancer: a comparison of family
physician versus specialist care. Journal of Clinical
Oncology, 2006; 24: 848–855. 11 Brennan M, Butow P, Spillane AJ, Marven M,
Boyle FM. Follow up after breast cancer – views of Australian women. Australian Family Physician,
2011; 40: 311–316. 12 Brennan ME, Butow P, Marven M, Spillane AJ,
Boyle FM. Survivorship care after breast cancer
treatment–experiences and preferences of Australian women. Breast, 2011; 20: 271–277.
13 Kantsiper M, McDonald EL, Geller G, Shockney
L, Snyder C, Wolff AC. Transitioning to breast
cancer survivorship: perspectives of patients, cancer
specialists, and primary care providers. Journal of
General Internal Medicine, 2009; 24(Suppl. 2): S459– S466.
14 Adewuyi-Dalton R, Ziebland S, Grunfeld E, Hall
A. Patients’ views of routine hospital follow-up: a
qualitative study of women with breast cancer in
remission. Psychooncology, 1998; 7: 436–439. 15 Knottnerus JA, ten Velden GH. Dutch doctors and
their patients–effects of health care reform in the Netherlands. New England Journal of Medicine,
2007; 357: 2424–2426. 16 Nationaal Borstkanker Overleg Nederland.
Mammacarcinoom. Landelijke richtlijn. Versie 1.1.
Amsterdam: Vereniging van Integrale Kankercentra,
2008.
17 Nederlands Huisartsen Genootschap. NHG-
Standaard Diagnostiek van mammacarcinoom.
Utrecht: Nederlands Huisartsen Genootschap,
2008.
18 Roorda C, de Bock GH, van der Veen WJ,
Lindeman A, Jansen L, van der Meer K. Role of
the general practitioner during the active breast
cancer treatment phase: an analysis of health care
use. Supportive Care in Cancer, 2012; 20: 705–714. 19 Borst-Eilers E. A welcome guide for evaluating
medical research involving human subjects.
Nederlands Tijdschrift voor Geneeskunde, 2003; 147:
898–900. 20 Hearnshaw H. Comparison of requirements of
research ethics committees in 11 European countries
for a non-invasive interventional study. British
Medical Journal, 2004; 328: 140–141. 21 Silverman D. Interpreting Qualitative Data: A Guide
to the Principles of Qualitative Research, 4th edn.
London: SAGE, 2011.
22 Miles MB, Huberman AM. Qualitative Data
Analysis. An Expanded Sourcebook, 2nd edn.
London: SAGE, 1994.
23 De Bock GH, Van Kampen IM, Van der Goot JH
et al. Transfer of information on palliative home
care during the out-of-hours period. Family
Practice, 2011; 28: 280–286. 24 Montgomery DA, Krupa K, Wilson C, Cooke TG.
Patients’ expectations for follow-up in breast
cancer–a preliminary, questionnaire-based study. Breast, 2008; 17: 347–352.
25 Lafferty J, Rankin F, Duffy C et al. Continuity of
care for women with breast cancer: a survey of the
views and experiences of patients, carers and health
care professionals. European Journal of Oncology
Nursing, 2011; 15: 419–427. 26 Pennery E, Mallet J. A preliminary study of
patients’ perceptions of routine follow-up after
treatment for breast cancer. European Journal of
Oncology Nursing, 2000; 4: 138–145; discussion 146–7.
27 Grunfeld E, Fitzpatrick R, Mant D et al.
Comparison of breast cancer patient satisfaction
with follow-up in primary care versus specialist
care: results from a randomized controlled trial.
British Journal of General Practice, 1999; 49:
705–710. 28 Mao JJ, Bowman MA, Stricker CT et al. Delivery
of survivorship care by primary care physicians: the
perspective of breast cancer patients. Journal of
Clinical Oncology, 2009; 27: 933–938. 29 Thind A, Liu Y, Maly RC. Patient satisfaction with
breast cancer follow-up care provided by family
physicians. Journal of the American Board of Family
Medicine, 2011; 24: 710–716. 30 Grunfeld E. Optimizing follow-up after breast
cancer treatment. Current Opinion in Obstetrics and
Gynecology, 2009; 21: 92–96. 31 Ganz PA, Hahn EE. Implementing a survivorship
care plan for patients with breast cancer. Journal of
Clinical Oncology, 2008; 26: 759–767. 32 Grunfeld E, Earle CC. The interface between
primary and oncology specialty care: treatment
through survivorship. Journal of the National Cancer
Institute. Monographs, 2010; 2010: 25–30. 33 Broom A, Hand K, Tovey P. The role of gender,
environment and Individual biography in shaping
qualitative interview data. International Journal of
Social Research Methodology, 2009; 12: 51–65.
ª 2014 John Wiley & Sons Ltd Health Expectations, 18, pp.2192–2201
Patients’ preferences for breast cancer follow-up, C Roorda et al. 2201
Copyright of Health Expectations is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.